Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Research on the links between tenofovir and other antiretrovirals, SARS-CoV-2 infection and COVID severity has produced mixed results.
Monoclonal antibodies used to prevent COVID-19 in immunocompromised people aren’t active against new virus variants.
Before they get COVID, people over 65 should have a plan for accessing antiviral treatment.
Paxlovid and molnupiravir can reduce the risk of severe COVID-19, but they must be started within five days of symptom onset.
Molnupiravir is authorized for people at high risk for severe COVID-19 when other treatment options are not available.
Molnupiravir, the first oral antiviral for COVID-19, reduces the risk of hospitalization or death if started within five days.
The new drugs must be used within a narrow window of time after developing symptoms.
Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.
Paxlovid dramatically reduced the risk of severe illness and death, but it must be started soon after developing symptoms.
Post-exposure and pre-exposure prophylaxis could be a game-changer for immunocompromised people.
Molnupiravir, previously studied for hepatitis C, might be able to prevent or treat COVID-19 outside of a clinical setting.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.